Roivant in talks to sell bowel disease drug to Roche in over $7 billion deal – WSJ
(Reuters) -Biotech company Roivant Sciences is in talks to sell an experimental drug to treat inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease, to Roche in a deal that could be valued at more than $7 billion, the Wall Street Journal reported on Thursday. The sale of the drug could be announced in the …
Roivant in talks to sell bowel disease drug to Roche in over $7 billion deal – WSJ Read More »










